{
  "id": "9d623bb7f06476f4",
  "title": "BridgeBio Pharma , Inc . Announces Positive Topline Results from PROPEL 3 , Global Phase 3 Pivotal Study of Oral Infigratinib in Children Living with Achondroplasia",
  "description": "20260212T140000Z",
  "content": "",
  "source": "marketscreener.com",
  "source_url": "https://www.marketscreener.com/news/bridgebio-pharma-inc-announces-positive-topline-results-from-propel-3-global-phase-3-pivotal-stud-ce7e5ad3d98cf520",
  "published_at": "20260212T140000Z",
  "fetched_at": "2026-02-13T00:31:20.432552+00:00",
  "category": "health_biotech",
  "subcategory": null,
  "keywords": [],
  "location": "",
  "raw_data": {
    "url": "https://www.marketscreener.com/news/bridgebio-pharma-inc-announces-positive-topline-results-from-propel-3-global-phase-3-pivotal-stud-ce7e5ad3d98cf520",
    "url_mobile": "",
    "title": "BridgeBio Pharma , Inc . Announces Positive Topline Results from PROPEL 3 , Global Phase 3 Pivotal Study of Oral Infigratinib in Children Living with Achondroplasia",
    "seendate": "20260212T140000Z",
    "socialimage": "https://www.marketscreener.com/images/twitter_MS_fdblanc.png",
    "domain": "marketscreener.com",
    "language": "English",
    "sourcecountry": ""
  }
}